- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07369557
Mindfulness-trening under akselerert iTBS for depresjon (MB-TBS)
MB-TBS: Bevissthetsbasert Theta-Burst Stimulering – En pilotstudie som integrerer bevissthetstrening i akselerert nevromodulasjonsterapi for depresjon
This NIH-funded single-arm pilot tests the feasibility, acceptability, and preliminary effects of embedding brief guided mindfulness practice (via the Waking Up smartphone app) into the inter-session intervals of clinically administered accelerated intermittent theta-burst stimulation (aiTBS) for major depressive disorder (MDD). Participants receive aiTBS as standard clinical care at MUSC; the research intervention is daily guided mindfulness practice during the aiTBS course. Outcomes include feasibility/acceptability, changes in state mindfulness and hedonic tone (Day 0 to Day 5), perceived ease of meditation, trait mindfulness at 4 and 12 weeks, and durability of antidepressant response (PHQ-9) at 4 and 12 weeks.
Studieoversikt
Status
Forhold
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
South Carolina
-
Charleston, South Carolina, Forente stater, 29407
- Rekruttering
- IOP
-
Ta kontakt med:
- Danyal Smani, MD
- Telefonnummer: 1 843 243 7306
- E-post: claytonolash@gmail.com
-
Charleston, South Carolina, Forente stater, 29407
- Har ikke rekruttert ennå
- Medical University of South Carolina (MUSC), Brain Stimulation Laboratory Institute of Psychiatry
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Clinical diagnosis of MDD and eligible for aiTBS at MUSC
- Already enrolled in aiTBS course at MUSC
- English proficiency
- Smartphone or willingness to use study-provided device
Exclusion Criteria:
- TMS contraindications (e.g., seizure history, implants, pregnancy)
- Concurrent neuromodulation (ECT, VNS)
- Psychotic disorder, bipolar disorder, active substance use disorder, high suicide risk
- Unable/unwilling to engage in mindfulness or complete questionnaires
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Awarenessstrening under aiTBS
|
5-15 minutes of mindfulness exercises during aiTBS inter-session intervals (9 total per day) for five consecutive treatment days; optional additional practices allowed. App analytics (with permission) and self-reports quantify engagement. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Feasibility of Guided Mindfulness Practice During aiTBS (Adherence Rate)
Tidsramme: Day 0 to Day 5
|
Proportion of participants who complete all mandatory guided practice on each of the five aiTBS treatment days. Calculated as: number completing all five days ÷ total enrolled. Higher values indicate better feasibility. |
Day 0 to Day 5
|
|
Tolerability of Guided Mindfulness Practice During aiTBS (Adverse Events)
Tidsramme: Day 0 to Day 5
|
Number and severity of meditation-related adverse events recorded via participant report and study staff observation. Higher values indicate worse tolerability. |
Day 0 to Day 5
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in State Mindfulness (Toronto Mindfulness Scale Total Score)
Tidsramme: Day 0 to Day 5
|
Change in Toronto Mindfulness Scale (TMS) total score from baseline to Day 5. Higher scores indicate greater state mindfulness. |
Day 0 to Day 5
|
|
Change in Hedonic Tone (Snaith-Hamilton Pleasure Scale Total Score)
Tidsramme: Day 0 to Day 5
|
Change in Snaith-Hamilton Pleasure Scale (SHAPS) total score from baseline to Day 5. Lower scores indicate improved hedonic tone. |
Day 0 to Day 5
|
|
Change in Perceived Ease of Meditation (0-10 Rating)
Tidsramme: Day 0 to Day 5
|
Change in meditation ease rating on a 0-10 numeric scale (0 = not at all easy; 10 = extremely easy). Higher scores indicate greater perceived ease. |
Day 0 to Day 5
|
|
Change in Trait Mindfulness (CAMS-R Total Score)
Tidsramme: Baseline to Week 12 (with Week-4 assessment)
|
Change in Cognitive and Affective Mindfulness Scale-Revised (CAMS-R) total score from baseline to Week 12. Higher scores indicate greater trait mindfulness. |
Baseline to Week 12 (with Week-4 assessment)
|
|
Durability of Antidepressant Response (Percent Change in PHQ-9)
Tidsramme: Baseline to Week 4
|
Percent change in PHQ-9 total score from baseline to Week 4. Lower scores indicate improvement |
Baseline to Week 4
|
|
Meditation Engagement (App Analytics and Self-Report)
Tidsramme: Day 0 to Week 12
|
Engagement with the Waking Up app measured by total minutes practiced, number of Foundations completed, and cumulative meditation minutes. Higher values indicate greater engagement. |
Day 0 to Week 12
|
Samarbeidspartnere og etterforskere
Etterforskere
- Hovedetterforsker: Clayton Olash, MD, Medical University of South Carolina
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- Pro00148491
- R25DA020537 (U.S. NIH-stipend/kontrakt)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-delingstidsramme
Within 12 months of study completion
IPD-deling Støtteinformasjonstype
- STUDY_PROTOCOL
- ICF
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .